REG - Poolbeg Pharma PLC - POLB 001 Oncology Programme Update Meeting

Poolbeg PharmaAnnouncement

01/11/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231101:nRSA9458Ra&default-theme=true

RNS Number : 9458R  Poolbeg Pharma PLC  01 November 2023

Poolbeg Pharma plc

 

Notice of POLB 001 Oncology Programme Update Meeting

 

1 November 2023 - Poolbeg Pharma (http://www.poolbegpharma.com/)  (AIM:
POLB, OTCQB: POLBF, 'Poolbeg' or the 'Company'), a clinical-stage
biopharmaceutical company targeting diseases with a high unmet medical need,
announces that it will host a meeting for investors and analysts on the POLB
001 Oncology Programme on Monday 6 November 2023 at 2:00pm - 3:30pm GMT via
the Investor Meet Company platform
(https://www.investormeetcompany.com/poolbeg-pharma-plc/register-investor) .
 

 

The event will provide an update and greater detail on Poolbeg's POLB 001
Oncology programme, which is targeting the Cytokine Release Syndrome (CRS)
associated with many cancer immunotherapy treatments. Severe cases of CRS are
life-threatening and may require intensive supportive care, including
mechanical ventilation. An effective treatment for CRS has the potential to
make these cancer immunotherapies more accessible, while reducing the
potentially life-threatening side effects impacting patients and healthcare
systems worldwide.

 

The meeting will be led by Jeremy Skillington, PhD, Chief Executive Officer,
and will feature presentations from a number of key opinion leaders and a
patient advocate. The meeting will be followed by a Q&A with the guest
speakers and Poolbeg's senior management.

 

Dr Martin Kaiser, team leader of the Myeloma Molecular Therapy group at the
Institute of Cancer Research and Honorary Consultant Haematologist at The
Royal Marsden NHS Foundation Trust

Presentation: Current innovations and future outlook in immunotherapy in
cancer. The challenges in safely and effectively delivering these therapies to
patients.

 

Bob Munroe, Myeloma Patient Advocate

Presentation: A patients' perspective: the need for broader access to
immunotherapies in cancer, through optimised side effect management.

 

Professor Brendan Buckley, Scientific Advisory Board Member and Honorary
Clinical Professor at University College Cork and University College Dublin

Presentation: POLB 001 as a potential treatment to manage Cytokine Release
Syndrome (CRS) associated with onco-immunotherapies and other acute
inflammatory conditions.

 

Registration

The presentation is open to all existing and potential shareholders. Questions
can be submitted in advance via your Investor Meet Company dashboard up until
9am the day before the meeting or at any time during the live presentation.

 

Investors can sign up to Investor Meet for free and add Poolbeg Pharma plc to
their company dashboard via:

https://www.investormeetcompany.com/poolbeg-pharma-plc/register-investor
(https://www.investormeetcompany.com/poolbeg-pharma-plc/register-investor)

 

Investors who already follow Poolbeg on the Investor Meet Company platform
will automatically be invited.

 

- Ends -

 

Enquiries

 Poolbeg Pharma Plc                                                    +44 (0) 207 183 1499

 Jeremy Skillington, CEO

 Ian O'Connell, CFO

 Cavendish Capital Markets Ltd (Nominated Adviser & Joint Broker)      +44 (0) 207 220 0500

 Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward (ECM)

 Singer Capital Markets (Joint Broker)                                  +44 (0) 207 496 3000

 Phil Davies, Sam Butcher

 J&E Davy (Joint Broker)                                               +353 (0) 1 679 6363

 Anthony Farrell, Niall Gilchrist

 Optimum Strategic Communications                                      +44 (0) 208 078 4357

 Nick Bastin, Hana Malik, Vici Rabbetts                                poolbeg@optimumcomms.com (mailto:poolbeg@optimumcomms.com)

 

About Poolbeg Pharma

Poolbeg Pharma specialises in the development of innovative medicines to
address the unmet need in infectious and other prevalent diseases. Poolbeg
Pharma has a disciplined portfolio approach to mitigate risk, accelerate drug
development, and enhance investor returns. The Company simultaneously advances
multiple programmes in cost-effective clinical trials, rapidly generating
early human safety and efficacy data to enable early partnering /
out-licensing, with the funds generated reinvested in the pipeline. Poolbeg
Pharma also uses AI to interrogate human challenge trial data sets to quickly
identify new targets and drugs, leading to faster development and greater
commercial appeal.

 

The Company is targeting the growing infectious disease market. In the wake of
the COVID-19 pandemic, infectious disease has become one of the fastest
growing pharma markets and is expected to exceed $250bn by 2025. Through
opportunistic identification of assets which complement Poolbeg Pharma's
existing pipeline, the Company is progressing programmes in oncology and
metabolic syndromes; adding disease areas with significant addressable
markets.

 

With its initial assets from hVIVO plc (http://www.hvivo.com/) , an industry
leading infectious disease and human challenge trials business, Poolbeg Pharma
has access to knowledge, experience, and clinical data from over 20 years of
human challenge trials. The Company is using these insights to acquire new
assets as well as reposition clinical stage products, reducing spend and risk.
Amongst its portfolio of exciting assets, Poolbeg Pharma has a small molecule
immunomodulator for severe influenza and other acute inflammatory
conditions (POLB 001) which produces a highly significant reduction in p38
MAP kinase driven cytokines in a clinical setting; a first-in-class,
intranasally administered RNA-based immunotherapy for respiratory virus
infections (POLB 002); and a vaccine candidate for Melioidosis (POLB 003). The
Company is progressing two Artificial Intelligence (AI) Programmes to add
promising new assets to its pipeline as well as developing an Oral Vaccine
Programme and an Oral Delivery Programme focussing on metabolic syndrome
related diseases.

 

For more information, please go to www.poolbegpharma.com
(http://www.poolbegpharma.com/)  or follow us on Twitter
(https://twitter.com/PoolbegPharma)  and LinkedIn
(https://www.linkedin.com/company/poolbeg-pharma/) @PoolbegPharma.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUAARROVUROUA